| Literature DB >> 25628407 |
Jia Zhong1, Elena Colicino1, Xinyi Lin2, Amar Mehta1, Itai Kloog3, Antonella Zanobetti1, Hyang-Min Byun1, Marie-Abèle Bind4, Laura Cantone5, Diddier Prada1, Letizia Tarantini5, Letizia Trevisi1, David Sparrow6, Pantel Vokonas6, Joel Schwartz1, Andrea A Baccarelli1.
Abstract
BACKGROUND: Short-term fine particles (PM(2.5)) exposure is associated with reduced heart rate variability, a strong predictor of cardiac mortality among older people. Identifying modifiable factors that confer susceptibility is essential for intervention. We evaluated whether Toll-like receptor 2 (TLR2) methylation, a reversible immune-epigenetic process, and its dietary modulation by flavonoids and methyl nutrients, modify susceptibility to heart rate variability effects following PM(2.5) exposure. METHODS ANDEntities:
Keywords: epidemiology; epigenetics; heart rate variability; inflammation; nutrition
Mesh:
Substances:
Year: 2015 PMID: 25628407 PMCID: PMC4330067 DOI: 10.1161/JAHA.114.001423
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1.The study participants in the Normative Aging Study, 2000–2011. PM2.5 indicates particulate matter with aerodynamic diameter <2.5 μm; TLR2, Toll‐like receptor 2. *In each analysis, some additional participants may have been excluded due to missing key study variables. We have noted in each table the corresponding sample size.
Figure 2.Schematic view of the genomic structure and CpG dinucleotides selected for analysis in the Toll‐like receptor 2 (TLR2) gene. The chromosomal location of the PCR amplicon for the TLR2 gene pyrosequencing assay is based on the Human Genome Assembly 2009 (GRC37/hg19) (UCSC Genome Browser). The CpG island, gene promoter region, PSQ CpG sites, PCR primer, and PSQ sequence primer location are shown in the figure. TSS indicates the transcription start site; PCR, polymerase chain reaction; PSQ, pyrosequencing. Position 1: CpG154605258; Position 2: CpG154605262; Position 3: CpG154605264; Position 4: CpG154605272; Position 5: CpG154605276.
Baseline Characteristics of Study Participants (N=573), 48‐Hour Moving Average of PM2.5, and Averaged Methylation Across CpG Positions in the Promoter Region of TLR2 Gene
| Characteristics | N (%) | Mean (SD) | |
|---|---|---|---|
| PM2.5 (μg/m3) | |||
| Age, y | |||
| 55 to 69 | 176 (30.7) | 11.4 (5.2) | 2.9 (1.3) |
| 70 to 79 | 293 (51.1) | 11.7 (6.4) | 3.1 (1.3) |
| 80 to 89 | 97 (16.9) | 10.6 (6.1) | 2.9 (1.1) |
| >90 | 7 (1.2) | 13.0 (5.0) | 3.4 (1.0) |
| Physical activity, MET‐h/wk | |||
| <12 | 371 (64.8) | 11.4 (6.3) | 2.93 (1.2) |
| 12 to <30 | 114 (19.9) | 11.3 (5.3) | 3.14 (1.4) |
| ≥30 | 88 (15.4) | 11.7 (5.5) | 3.08 (1.2) |
| Alcohol (drinks/d) | |||
| ≥2 | 106 (18.5) | 11.6 (6.7) | 2.9 (1.1) |
| <2 | 467 (81.5) | 11.4 (5.8) | 3.0 (1.2) |
| Diabetes | |||
| Yes | 111 (19.4) | 11.0 (6.0) | 2.9 (1.0) |
| No | 462 (80.6) | 11.5 (6.0) | 3.0 (1.3) |
| Race | |||
| White | 549 (95.8) | 11.4 (5.9) | 3.0 (1.3) |
| Nonwhite | 24 (4.2) | 11.6 (7.7) | 2.8 (0.9) |
| Hypertension | |||
| Yes | 405 (70.7) | 11.3 (6.0) | 3.0 (1.3) |
| No | 168 (29.3) | 11.8 (6.0) | 2.9 (1.2) |
| BMI, kg/m2 | |||
| <25 | 123 (21.5) | 12.4 (6.8) | 3.0 (1.2) |
| ≥25 | 450 (78.5) | 11.2 (5.7) | 3.0 (1.3) |
| Smoking | |||
| Never | 166 (29.0) | 11.7 (6.0) | 3.1 (1.4) |
| Current | 26 (4.5) | 10.9 (3.8) | 3.3 (1.1) |
| Former | 381 (66.5) | 11.4 (6.1) | 2.9 (1.2) |
| Annual income >$60 000 | |||
| Yes | 272 (47.5) | 11.0 (5.4) | 3.1 (1.3) |
| No | 301 (52.5) | 11.8 (6.5) | 2.9 (1.2) |
BMI indicates body mass index; MET, metabolic equivalent of task; PM2.5, particulate matter with aerodynamic diameter <2.5 μm; TLR2, Toll‐like receptor 2.
Effect of 48‐Hour Moving Average of PM2.5 on HRV, Normative Aging Study, 2000–2011 (N=500)
| HRV Measure | Change in HRV Per 10 μg/m3 Increase in PM2.5 Concentration | ||
|---|---|---|---|
| % Change | 95% CI | ||
| HR | 0.42 | −0.94 to 1.80 | 0.55 |
| rMSSD | −7.74 | −15.90 to 1.21 | 0.09 |
| SDNN | −7.46 | −13.50 to −0.99 | 0.02 |
| LF | −14.18 | −25.49 to −1.14 | 0.03 |
| HF | −12.94 | −25.96 to 2.36 | 0.09 |
HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM2.5, particulate matter with aerodynamic diameter <2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals.
Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.
Effect of 48‐Hour Moving Average of Black Carbon, Carbon Monoxide, Nitrogen Dioxide, and Ozone on HRV, Normative Aging Study, 2000–2011 (N=573)
| HRV | Black Carbon | Carbon Monoxide | Nitrogen Dioxide | Ozone | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % Change | 95% CI | % Change | 95% CI | % Change | 95% CI | % Change | 95% CI | |||||
| HR | 0.04 | −0.82 to 0.92 | 0.92 | −0.97 | −3.16 to 1.28 | 0.40 | 0.25 | −0.76 to 1.27 | 0.63 | −0.92 | −2.19 to 0.37 | 0.16 |
| rMSSD | −2.02 | −7.59 to 3.88 | 0.49 | −1.86 | −15.63 to 14.15 | 0.81 | −3.71 | −10.08 to 3.11 | 0.28 | −5.31 | −13.2 to 3.3 | 0.22 |
| SDNN | −2.28 | −6.36 to 1.98 | 0.29 | −2.19 | −12.42 to 9.23 | 0.69 | −1.93 | −6.72 to 3.1 | 0.44 | −4.13 | −10.04 to 2.17 | 0.19 |
| LF | −2.46 | −10.82 to 6.68 | 0.59 | −1.61 | −21.91 to 23.96 | 0.89 | −1.55 | −11.31 to 9.3 | 0.77 | −5.92 | −17.66 to 7.5 | 0.37 |
| HF | −1.91 | −11.45 to 8.67 | 0.71 | −2.55 | −25.13 to 26.86 | 0.85 | −7.29 | −17.7 to 4.44 | 0.21 | −5.19 | −18.57 to 10.39 | 0.49 |
HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals.
Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.
Effect of PM2.5 Exposure on HRV at Different Mean TLR2 Methylation Levels, Normative Aging Study, 2000–2011 (N=500)
| Mean | % Change | 95% CI | |
|---|---|---|---|
| HR | |||
| Midpoint of Q1 (1.5 5mc%) | −0.56 | −2.88 to 1.82 | 0.64 |
| Midpoint of Q2 (2.2 5mc%) | −0.10 | −1.99 to 1.81 | 0.92 |
| Midpoint of Q3 (3.0 5mc%) | 0.42 | −1.25 to 2.11 | 0.62 |
| Midpoint of Q4 (4.4 5mc%) | 1.34 | −0.92 to 3.66 | 0.25 |
| 0.62 | |||
| rMSSD | |||
| Midpoint of Q1 (1.5 5mc%) | 8.77 | −7.55 to 27.95 | 0.31 |
| Midpoint of Q2 (2.2 5mc%) | −1.01 | −13.14 to 12.81 | 0.88 |
| Midpoint of Q3 (3.0 5mc%) | −11.11 | −20.87 to −0.16 | 0.05 |
| Midpoint of Q4 (4.4 5mc%) | −26.38 | −37.20 to −13.69 | 0.0002 |
| 0.006 | |||
| SDNN | |||
| Midpoint of Q1 (1.5 5mc%) | −0.39 | −11.76 to 12.45 | 0.95 |
| Midpoint of Q2 (2.2 5mc%) | −3.85 | −12.78 to 6.00 | 0.43 |
| Midpoint of Q3 (3.0 5mc%) | −7.65 | −15.31 to 0.71 | 0.07 |
| Midpoint of Q4 (4.4 5mc%) | −13.94 | −23.55 to −3.12 | 0.01 |
| 0.03 | |||
| LF | |||
| Midpoint of Q1 (1.5 5mc%) | −7.25 | −27.74 to 19.06 | 0.56 |
| Midpoint of Q2 (2.2 5mc%) | −10.88 | −27.11 to 8.96 | 0.26 |
| Midpoint of Q3 (3.0 5mc%) | −14.86 | −28.80 to 1.81 | 0.08 |
| Midpoint of Q4 (4.4 5mc%) | −21.40 | −38.47 to 0.39 | 0.05 |
| 0.05 | |||
| HF | |||
| Midpoint of Q1 (1.5 5mc%) | 10.06 | −16.25 to 44.64 | 0.49 |
| Midpoint of Q2 (2.2 5mc%) | −2.82 | −22.02 to 21.10 | 0.80 |
| Midpoint of Q3 (3.0 5mc%) | −15.71 | −30.75 to 2.60 | 0.09 |
| Midpoint of Q4 (4.4 5mc%) | −34.28 | −49.87 to −13.84 | 0.003 |
| 0.04 | |||
Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date. Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartile. HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM2.5, particulate matter with aerodynamic diameter <2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; TLR2, Toll‐like receptor 2.
The percent change in HRV per 10 μg/m3 increase in PM2.5 concentration.
Based on a global test for effect modification by position‐specific methylation. Interaction terms between each of the 5 TLR2 positions and PM2.5 were included in the model, and these 5 interaction terms were tested jointly for effect modification using a Wald test (global test).
Figure 3.The effect of particulate matter with aerodynamic diameter <2.5 μm (PM2.5) exposure on heart rate variability (HRV) at different mean Toll‐like receptor 2 (TLR2) methylation levels, Normative Aging Study, 2000–2011 (N=500). log10HR indicates log10‐transformed heart rate; log10rMSSD, log10‐transformed root mean square of the successive differences; log10SDNN, log10‐transformed standard deviation of normal‐to‐normal intervals; log10LF, log10‐transformed low‐frequency power (0.04 to 0.15 Hz); log10HF, log10‐transformed high‐frequency power (0.15 to 0.4 Hz); Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartiles. The association of PM2.5 with rMSSD, SDNN, LF, and HF is modified by mean TLR2 methylation levels, as indicated by the different slopes. The 4 lines in each figure represent the relationship between PM2.5 and HRV when the mean TLR2 methylation level is at the midpoints of each quartile. If there was no effect modification, the 4 lines would be the same. The Pglobal for interaction was based on a global test for effect modification by position‐specific methylation. Interaction terms between each of the 5 TLR2 positions and PM2.5 were included in the model, and these 5 interaction terms were tested jointly for effect modification using a Wald test (global test). Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.
Effect Modification by Position‐Specific TLR2 Methylation on the Association Between PM2.5 Exposure and HRV (N=500)
| Position | Methylation | % Change | 95% CI | % Change | 95% CI | % Change | 95% CI | |||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | rMSSD | SDNN | ||||||||
| 1 | Midpoint of Q1 | 0.36 | −1.96 to 2.75 | 0.76 | 7.26 | −8.65 to 25.94 | 0.39 | 1.66 | −9.79 to 14.56 | 0.79 |
| Midpoint of Q2 | 0.42 | −1.38 to 2.24 | 0.65 | −4.56 | −15.66 to 8.01 | 0.46 | −4.30 | −12.71 to 4.93 | 0.35 | |
| Midpoint of Q3 | 0.46 | −1.22 to 2.17 | 0.60 | −13.25 | −22.84 to −2.47 | 0.02 | −8.91 | −16.51 to −0.63 | 0.04 | |
| Midpoint of Q4 | 0.53 | −1.72 to 2.83 | 0.65 | −26.01 | −36.84 to −13.31 | 0.0002 | −16.11 | −25.42 to −5.64 | 0.004 | |
| 0.92 | 0.0009 | 0.02 | ||||||||
| 2 | Midpoint of Q1 | 0.08 | −2.12 to 2.34 | 0.94 | −0.21 | −14.47 to 16.43 | 0.98 | −7.00 | −17.08 to 4.3 | 0.22 |
| Midpoint of Q2 | 0.28 | −1.49 to 2.09 | 0.76 | −6.61 | −17.49 to 5.72 | 0.28 | −7.36 | −15.51 to 1.58 | 0.10 | |
| Midpoint of Q3 | 0.44 | −1.23 to 2.13 | 0.61 | −11.33 | −21.1 to −0.35 | 0.04 | −7.64 | −15.31 to 0.73 | 0.07 | |
| Midpoint of Q4 | 0.75 | −1.4 to 2.95 | 0.50 | −20.06 | −31.31 to −6.98 | 0.004 | −8.20 | −17.98 to 2.74 | 0.14 | |
| 0.65 | 0.03 | 0.86 | ||||||||
| 3 | Midpoint of Q1 | −0.82 | −3.19 to 1.61 | 0.51 | 5.96 | −10.3 to 25.17 | 0.50 | 1.15 | −10.63 to 14.49 | 0.86 |
| Midpoint of Q2 | −0.16 | −1.99 to 1.71 | 0.86 | −3.69 | −15.24 to 9.44 | 0.56 | −3.72 | −12.44 to 5.87 | 0.43 | |
| Midpoint of Q3 | 0.37 | −1.3 to 2.07 | 0.67 | −10.77 | −20.6 to 0.28 | 0.06 | −7.44 | −15.13 to 0.94 | 0.08 | |
| Midpoint of Q4 | 1.27 | −0.85 to 3.44 | 0.24 | −21.64 | −32.48 to −9.05 | 0.00 | −13.45 | −22.51 to −3.33 | 0.01 | |
| 0.18 | 0.005 | 0.05 | ||||||||
| 4 | Midpoint of Q1 | −0.28 | −2.62 to 2.12 | 0.82 | 2.48 | −12.89 to 20.56 | 0.77 | −4.43 | −15.3 to 7.83 | 0.46 |
| Midpoint of Q2 | 0.11 | −1.73 to 1.99 | 0.90 | −4.88 | −16.33 to 8.13 | 0.44 | −6.13 | −14.66 to 3.25 | 0.19 | |
| Midpoint of Q3 | 0.45 | −1.22 to 2.15 | 0.60 | −10.81 | −20.64 to 0.23 | 0.06 | −7.57 | −15.25 to 0.8 | 0.08 | |
| Midpoint of Q4 | 1.10 | −1.08 to 3.32 | 0.33 | −21.06 | −32.16 to −8.15 | 0.002 | −10.25 | −19.8 to 0.45 | 0.06 | |
| 0.38 | 0.01 | 0.43 | ||||||||
| 5 | Midpoint of Q1 | −1.24 | −3.63 to 1.2 | 0.32 | 6.37 | −9.99 to 25.69 | 0.47 | 1.72 | −10.17 to 15.19 | 0.79 |
| Midpoint of Q2 | −0.31 | −2.15 to 1.57 | 0.75 | −3.71 | −15.29 to 9.45 | 0.56 | −3.62 | −12.39 to 6.02 | 0.45 | |
| Midpoint of Q3 | 0.48 | −1.2 to 2.18 | 0.58 | −11.31 | −21.05 to −0.36 | 0.04 | −7.82 | −15.46 to 0.52 | 0.07 | |
| Midpoint of Q4 | 1.81 | −0.34 to 4 | 0.10 | −22.79 | −33.47 to −10.39 | 0.0007 | −14.49 | −23.45 to −4.47 | 0.006 | |
| 0.05 | 0.003 | 0.03 | ||||||||
| LF | HF | |||||||||
| 1 | Midpoint of Q1 | −11.35 | −30.67 to 13.36 | 0.34 | 1.00 | −22.87 to 32.27 | 0.94 | |||
| Midpoint of Q2 | −13.74 | −28.64 to 4.28 | 0.13 | −9.74 | −26.73 to 11.19 | 0.34 | ||||
| Midpoint of Q3 | −15.64 | −29.53 to 0.98 | 0.06 | −17.68 | −32.53 to 0.45 | 0.06 | ||||
| Midpoint of Q4 | −18.73 | −36.26 to 3.64 | 0.10 | −29.38 | −46.1 to −7.48 | 0.01 | ||||
| 0.61 | 0.06 | |||||||||
| 2 | Midpoint of Q1 | −17.70 | −34.99 to 4.19 | 0.11 | −5.94 | −27.43 to 21.91 | 0.64 | |||
| Midpoint of Q2 | −16.04 | −30.54 to 1.48 | 0.07 | −11.67 | −28.3 to 8.83 | 0.24 | ||||
| Midpoint of Q3 | −14.72 | −28.69 to 1.99 | 0.08 | −15.90 | −30.99 to 2.48 | 0.09 | ||||
| Midpoint of Q4 | −12.02 | −30.33 to 11.11 | 0.28 | −23.77 | −41.18 to −1.22 | 0.04 | ||||
| 0.67 | 0.22 | |||||||||
| 3 | Midpoint of Q1 | 4.93 | −18.73 to 35.46 | 0.71 | 10.57 | −16.54 to 46.49 | 0.48 | |||
| Midpoint of Q2 | −6.44 | −23.08 to 13.79 | 0.51 | −4.44 | −22.97 to 18.55 | 0.68 | ||||
| Midpoint of Q3 | −14.64 | −28.62 to 2.06 | 0.08 | −14.96 | −30.18 to 3.58 | 0.11 | ||||
| Midpoint of Q4 | −26.97 | −41.87 to −8.26 | 0.007 | −30.26 | −45.83 to −10.2 | 0.005 | ||||
| 0.03 | 0.01 | |||||||||
| 4 | Midpoint of Q1 | −12.69 | −31.92 to 11.98 | 0.29 | −0.15 | −24.04 to 31.25 | 0.99 | |||
| Midpoint of Q2 | −13.86 | −29.23 to 4.84 | 0.14 | −8.49 | −26.31 to 13.62 | 0.42 | ||||
| Midpoint of Q3 | −14.86 | −28.79 to 1.8 | 0.08 | −15.14 | −30.32 to 3.36 | 0.10 | ||||
| Midpoint of Q4 | −16.72 | −33.93 to 4.96 | 0.12 | −26.43 | −42.95 to −5.13 | 0.02 | ||||
| 0.77 | 0.09 | |||||||||
| 5 | Midpoint of Q1 | −1.26 | −23.57 to 27.57 | 0.92 | 15.29 | −12.68 to 52.22 | 0.32 | |||
| Midpoint of Q2 | −9.27 | −25.47 to 10.46 | 0.33 | −3.32 | −21.96 to 19.78 | 0.76 | ||||
| Midpoint of Q3 | −15.39 | −29.24 to 1.17 | 0.07 | −16.41 | −31.27 to 1.68 | 0.07 | ||||
| Midpoint of Q4 | −24.79 | −40.16 to −5.46 | 0.01 | −34.57 | −49.1 to −15.88 | 0.001 | ||||
| 0.10 | 0.002 | |||||||||
HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM2.5, particulate matter with aerodynamic diameter <2.5 μm; Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartile; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; TLR2, Toll‐like receptor 2.
The percent change in HRV per 10 μg/m3 increase in PM2.5 concentration. Results were adjusted for age; body mass index; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.
To examine effect modification by position‐specific TLR2 methylation, an interaction term between position‐specific TLR2 methylation and PM2.5 was included in the model.
Figure 4.Effect of dietary flavonoid (N=497) and folic acid (N=482) intake on mean and position‐specific Toll‐like receptor 2 (TLR2) methylation. IQR indicates interquartile range. Results were adjusted for age, body mass index, total caloric intake, total vitamin C intake, total fiber intake, smoking status, household income, and physical activity.
Effect of Dietary Flavonoid Intake on Mean and Position‐Specific TLR2 Methylation, Adjusted for Total Fruit and Vegetable Intake
| Original Model (N=497) | Adjusted for Total Fruit and Vegetable Intake (N=482) | |||||
|---|---|---|---|---|---|---|
| % Change | 95% CI | % Change | 95% CI | |||
| Position 1 | −10.02 | −17.37 to −2.66 | <0.01 | −8.47 | −15.94 to −1.01 | 0.03 |
| Position 2 | −3.81 | −10.31 to 2.69 | 0.25 | −2.51 | −9.33 to 4.30 | 0.48 |
| Position 3 | −4.49 | −12.11 to 3.14 | 0.25 | −4.28 | −12.11 to 3.55 | 0.28 |
| Position 4 | −6.05 | −12.74 to 0.65 | 0.08 | −6.61 | −13.51 to 0.29 | 0.06 |
| Position 5 | −3.31 | −14.26 to 7.64 | 0.55 | −4.82 | −16.12 to 6.48 | 0.41 |
| Mean | −5.09 | −10.06 to −0.12 | 0.05 | −4.99 | −10.16 to 0.17 | 0.06 |
TLR2 indicates Toll‐like receptor 2.
Results were adjusted for age, year of visit, body mass index, total caloric intake, total vitamin C intake, total fiber intake, smoking status, household income, and physical activity.
In addition to all the covariates in the original model except total vitamin C and fiber intake, results were adjusted for total fruit and vegetable intake.
Figure 5.Effect of dietary vitamin B12 (N=497) and methionine (N=482) intake on mean and position‐specific Toll‐like receptor 2 (TLR2) methylation. IQR indicates interquartile range. Results were adjusted for age, body mass index, total caloric intake, total vitamin C intake, total fiber intake, smoking status, household income, and physical activity.
Effect of PM2.5 Exposure on HRV at Different Daily Flavonoid Intake Levels, Normative Aging Study, 2000–2011 (N=513)
| Flavonoid Intake | % Change | 95% CI | |
|---|---|---|---|
| HR | |||
| Midpoint of Q1 (128 mg/d) | 0.06 | −1.65 to 1.80 | 0.95 |
| Midpoint of Q2 (228 mg/d) | 0.00 | −1.51 to 1.53 | 1.00 |
| Midpoint of Q3 (370 mg/d) | −0.09 | −1.45 to 1.30 | 0.90 |
| Midpoint of Q4 (673 mg/d) | −0.26 | −1.98 to 1.48 | 0.76 |
| 0.76 | |||
| rMSSD | |||
| Midpoint of Q1 (128 mg/d) | −5.32 | −16.91 to 7.88 | 0.41 |
| Midpoint of Q2 (228 mg/d) | −4.94 | −15.25 to 6.62 | 0.39 |
| Midpoint of Q3 (370 mg/d) | −4.41 | −13.82 to 6.03 | 0.39 |
| Midpoint of Q4 (673 mg/d) | −3.25 | −15.28 to 10.49 | 0.63 |
| 0.79 | |||
| SDNN | |||
| Midpoint of Q1 (128 mg/d) | −6.14 | −14.57 to 3.11 | 0.19 |
| Midpoint of Q2 (228 mg/d) | −5.22 | −12.74 to 2.95 | 0.20 |
| Midpoint of Q3 (370 mg/d) | −3.89 | −10.81 to 3.56 | 0.30 |
| Midpoint of Q4 (673 mg/d) | −1.00 | −10.03 to 8.93 | 0.84 |
| 0.37 | |||
| LF | |||
| Midpoint of Q1 (128 mg/d) | −16.48 | −31.35 to 1.61 | 0.07 |
| Midpoint of Q2 (228 mg/d) | −12.55 | −26.37 to 3.87 | 0.13 |
| Midpoint of Q3 (370 mg/d) | −6.65 | −20.07 to 9.03 | 0.39 |
| Midpoint of Q4 (673 mg/d) | 7.31 | −12.16 to 31.11 | 0.49 |
| 0.05 | |||
| HF | |||
| Midpoint of Q1 (128 mg/d) | −10.42 | −28.69 to 12.54 | 0.34 |
| Midpoint of Q2 (228 mg/d) | −7.78 | −24.49 to 12.63 | 0.43 |
| Midpoint of Q3 (370 mg/d) | −3.89 | −19.74 to 15.09 | 0.67 |
| Midpoint of Q4 (673 mg/d) | 4.96 | −16.93 to 32.63 | 0.68 |
| 0.28 |
Results were adjusted for age; body mass index; total caloric intake; total vitamin C intake; total fiber intake; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date. HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM2.5, particulate matter with aerodynamic diameter <2.5 μm; Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartile; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals.
The percent change in HRV per 10 μg/m3 increase in PM2.5 concentration.
Figure 6.The effect of particulate matter with aerodynamic diameter <2.5 μm (PM2.5) exposure on heart rate variability (HRV) at different flavonoid intake levels, Normative Aging Study, 2000–2011 (N=513). log10HR indicates log10‐transformed heart rate; log10rMSSD, log10‐transformed root mean square of the successive differences; log10SDNN, log10‐transformed standard deviation of normal‐to‐normal intervals; log10LF, log10‐transformed low‐frequency power (0.04 to 0.15 Hz); log10HF, log10‐transformed high‐frequency power (0.15 to 0.4 Hz); Q1, Q2, Q3, and Q4 indicate the first, second, third, and fourth quartiles. The association of PM2.5 on rMSSD, SDNN, LF, and HF is modified by flavonoid intake, as indicated by the different slopes. The 4 lines in each figure represent the relationship between PM2.5 and HRV when the flavonoid intake is at the midpoints of each quartile. If there was no effect modification, the 4 lines would be the same. Results were adjusted for age; body mass index; total caloric intake; total vitamin C intake; total fiber intake; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday; and visit date.
Effect Modification by Flavonoid Intake on the Association Between PM2.5 Exposure and HRV, Adjusted for Total Fruit and Vegetable Intake, and Adjusted for Mean TLR2 Methylation
| HRV Measure | Original Model (N=513) | Adjusted for Total Fruit and Vegetable Intake (N=482) | Adjusted for Mean | ||||||
|---|---|---|---|---|---|---|---|---|---|
| % Change | 95% CI | % Change | 95% CI | % Change | 95% CI | ||||
| HR | −0.18 | −1.32 to 0.98 | 0.76 | −0.30 | −1.48 to 0.90 | 0.62 | 0.89 | −0.72 to 2.52 | 0.30 |
| rMSSD | 1.17 | −7.38 to 10.51 | 0.79 | 0.67 | −8.45 to 10.7 | 0.89 | 0.07 | −11.28 to 12.87 | 0.99 |
| SDNN | 2.98 | −3.43 to 9.81 | 0.37 | 2.77 | −3.88 to 9.88 | 0.42 | 2.28 | −6.49 to 11.87 | 0.62 |
| LF | 14.63 | 0.27 to 31.03 | 0.05 | 15.81 | 0.50 to 33.45 | 0.04 | 10.48 | −8.39 to 33.24 | 0.30 |
| HF | 8.98 | −6.93 to 27.62 | 0.28 | 7.65 | −9.17 to 27.59 | 0.40 | 7.65 | −12.28 to 32.10 | 0.48 |
HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM2.5, particulate matter with aerodynamic diameter <2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; TLR2, Toll‐like receptor 2.
Results were adjusted for age; body mass index; total caloric intake; total vitamin C intake; total fiber intake; fasting glucose level; hypertension; smoking status; alcohol consumption; physical exercise; household income; the use of calcium channel blocker, β‐blocker, and angiotensin‐converting enzyme inhibitor; room temperature; outdoor apparent temperature; season; weekday, and visit date.
In addition to all the covariates in the original model except total vitamin C and fiber intake, results were adjusted for total fruit and vegetable intake.
In addition to all the covariates in the original model, results were adjusted for mean TLR2 methylation, and the interaction between mean TLR2 methylation and PM2.5 concentration.
The additional percent change in HRV associated with 10 μg/m3 PM2.5 concentration, compared to participants with 1 interquartile range lower flavonoid intake level.
Correlation Between Mean Blood TLR2 Methylation and Plasma Inflammatory Markers
| Position 1 | Position 2 | Position 3 | Position 4 | Position 5 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Correlation Coefficient | Correlation Coefficient | Correlation Coefficient | Correlation Coefficient | Correlation Coefficient | ||||||
| IL‐6 | −0.067 | 0.08 | −0.025 | 0.52 | 0.067 | 0.08 | 0.040 | 0.30 | 0.020 | 0.60 |
| IL‐8 | −0.004 | 0.93 | 0.006 | 0.88 | 0.095 | 0.01 | 0.053 | 0.17 | 0.049 | 0.20 |
| IL‐1β | −0.031 | 0.42 | 0.040 | 0.31 | 0.046 | 0.23 | 0.019 | 0.63 | 0.015 | 0.70 |
| TNF‐α | −0.043 | 0.27 | −0.056 | 0.15 | 0.006 | 0.87 | −0.009 | 0.81 | −0.039 | 0.32 |
| TNFγ | −0.030 | 0.44 | −0.007 | 0.86 | −0.017 | 0.66 | −0.029 | 0.45 | −0.022 | 0.58 |
| CRP | 0.032 | 0.35 | −0.007 | 0.85 | 0.011 | 0.76 | 0.024 | 0.49 | 0.047 | 0.17 |
| ICAM‐1 | 0.138 | <0.0001 | 0.159 | <0.0001 | 0.127 | 0.0002 | 0.123 | 0.0004 | 0.124 | 0.0003 |
| VEGF | −0.022 | 0.57 | −0.016 | 0.68 | 0.091 | 0.02 | 0.050 | 0.20 | 0.046 | 0.24 |
CRP indicates C‐reactive protein; ICAM‐1, intercellular adhesion molecule 1; IL, interleukin; TLR2, Toll‐like receptor 2; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
P value represents Prob>|r| under H0: ρ (Spearman's rank correlation coefficient)=0.
Correlation Between Mean Blood TLR2 Methylation Level and Proportions of Different Leukocyte Cell Types
| Cell Type (%) | Spearman Correlation With Mean | |
|---|---|---|
| Correlation Coefficient | ||
| Eosinophils | 0.051 | 0.145 |
| Lymphocytes | 0.121 | 0.001 |
| Neutrophils | −0.118 | 0.001 |
| Monocytes | 0.018 | 0.604 |
| Basophils | 0.012 | 0.730 |
TLR2 indicates Toll‐like receptor 2.
Mean TLR2 methylation level across 5 CpG sites.
P value represents Prob>|r| under H0: ρ (Spearman's rank correlation coefficient)=0.
Effect Modification by Position‐Specific TLR2 Methylation Level on the Association Between PM2.5 Exposure and HRV, Adjusted for Cell Types
| Position | % Change | % Change |
|---|---|---|
| HR | ||
| 1 | 0.05 | 0.03 |
| 2 | 0.17 | 0.26 |
| 3 | 0.53 | 0.60 |
| 4 | 0.36 | 0.44 |
| 5 | 0.83 | 0.85 |
| rMSSD | ||
| 1 | −10.07 | −9.64 |
| 2 | −5.60 | −6.10 |
| 3 | −7.35 | −7.45 |
| 4 | −6.55 | −6.48 |
| 5 | −8.29 | −7.88 |
| SDNN | ||
| 1 | −5.34 | −5.01 |
| 2 | −0.34 | −0.72 |
| 3 | −3.87 | −3.97 |
| 4 | −1.62 | −1.56 |
| 5 | −4.58 | −4.21 |
| LF | ||
| 1 | −2.45 | −1.65 |
| 2 | 1.75 | 1.39 |
| 3 | −8.77 | −8.90 |
| 4 | −1.22 | −1.23 |
| 5 | −7.09 | −6.46 |
| HF | ||
| 1 | −9.72 | −8.72 |
| 2 | −5.31 | −6.35 |
| 3 | −11.01 | −11.31 |
| 4 | −7.63 | −7.74 |
| 5 | −14.20 | −13.33 |
HF indicates high‐frequency power (0.15 to 0.4 Hz); HR, heart rate; HRV, heart rate variability; LF, low‐frequency power (0.04 to 0.15 Hz); PM2.5, particulate matter with aerodynamic diameter <2.5 μm; rMSSD, root mean square of successive differences; SDNN, standard deviation of normal‐to‐normal intervals; TLR2, Toll‐like receptor 2.
Results were adjusted for age, body mass index, fasting glucose level, hypertension, smoking status, alcohol consumption, physical exercise, household income, medication use (β‐blocker, calcium channel blocker, angiotensin‐converting enzyme inhibitor), room temperature, outdoor apparent temperature, season, weekday, and visit date.
Results were adjusted for all covariates in the original model and the percentage of neutrophil and lymphocyte.
P≤0.05, statistically significant.
The additional percent change in HRV associated with 10 μg/m3 increase in PM2.5 concentration, compared to participants with one %5mC lower TLR2 methylation level.